Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc director Daphne Karydas received a grant of share options covering 21,110 ordinary shares. These options have an exercise price of $11.85 per share and were awarded at no cost as a compensation grant.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual General Meeting of Shareholders, and they expire in 2036. Each ordinary share may be represented by one American Depositary Share.
COMPASS Pathways plc director Gino Santini received a grant of share options covering 30,158 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. Following this compensation award, Santini holds options for 30,158 shares, which may be exercised into Ordinary Shares that can be represented by American Depositary Shares on a one-for-one basis.
COMPASS Pathways plc director Justin D. Gover received a grant of share options over 21,110 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. The shares underlying this option vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. The options are held directly and may be exercised for Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to one Ordinary Share.
COMPASS Pathways plc director Jeffrey M. Jonas received a grant of share options linked to 21,110 Ordinary Shares. The options carry an exercise price of $11.85 per share and expire in 2036. They vest in full on the earlier of one year from grant or the company’s 2027 annual shareholder meeting.
COMPASS Pathways plc director Wayne Joseph Riley received a grant of share options covering 21,110 Ordinary Shares. These options were awarded at an exercise price of $11.85 per share and are held directly. Following the grant, his option holdings reported in this filing total 21,110 shares.
The option vests in full on the earlier of the first anniversary of the grant date or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027, and expires on May 26, 2036. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
COMPASS Pathways plc director Robert McQuade received a grant of share options covering 21,110 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. Following this award, he holds options for 21,110 shares directly.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. The underlying Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share.
COMPASS Pathways plc director David Y. Norton received a grant of share options giving him the right to buy 21,110 Ordinary Shares. The options have an exercise price of $11.85 per share and expire on 26 May 2036. The underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual General Meeting of Shareholders. The Ordinary Shares may be represented by American Depositary Shares on a 1:1 basis.
COMPASS Pathways plc director Kathleen Tregoning received a grant of share options covering 41,119 Ordinary Shares. The options have an exercise price of 11.85 per share and expire on May 26, 2036.
The award vests in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on June 27, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
COMPASS Pathways plc director Kathleen Tregoning has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing reports no transactions in COMPASS Pathways securities, and no derivative positions or other holdings are listed in the provided data.
Compass Pathways plc reported the results of its 2026 Annual General Meeting held on May 27, 2026. Shareholders representing 58,880,058 ordinary shares were present in person or by proxy. The company did not exercise discretionary voting power over American Depositary Shares lacking voting instructions, which were counted as broker non-votes.
Shareholders re-elected Justin Gover, Daphne Karydas and Jeffrey Jonas as directors and elected Kathleen Tregoning to the board. They also re-appointed PwC UK as U.K. statutory auditors, ratified PwC US as independent registered public accounting firm for 2026 and authorized the Audit and Risk Committee to determine auditors’ remuneration.
Investors approved the receipt of the U.K. statutory annual accounts for the year ended December 31, 2025 and noted that no dividend is recommended for that year. They also approved, on a non-binding, advisory basis, the directors’ remuneration report and the compensation of named executive officers. Following the meeting, Annalisa Jenkins’ eight-year term on the board concluded.